Skip to main content

Vitrectomy

2
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
3 programs
1
Triamcinolone Acetonide Injectable SuspensionPhase 31 trial
25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomyN/A1 trial
Utravit High-Speed 10000 cpm Beveled ProbeN/A1 trial
Active Trials
NCT04404296Unknown50Est. Jan 2022
NCT04076072Completed40Est. Jan 2022
NCT00532415Completed60Est. Sep 2007
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
400 µg Brimonidine Tartrate ImplantPhase 11 trial
Pars Plana VitrectomyN/A1 trial
Active Trials
NCT01319318Completed25Est. Jun 2012
NCT01229410Completed24Est. Oct 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlconTriamcinolone Acetonide Injectable Suspension
AbbVie400 µg Brimonidine Tartrate Implant
Alcon25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy
AlconUtravit High-Speed 10000 cpm Beveled Probe
AbbViePars Plana Vitrectomy

Clinical Trials (5)

Total enrollment: 199 patients across 5 trials

NCT00532415AlconTriamcinolone Acetonide Injectable Suspension

Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy

Start: Sep 2007Est. completion: Sep 200760 patients
Phase 3Completed
NCT01229410AbbVie400 µg Brimonidine Tartrate Implant

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

Start: Dec 2010Est. completion: Oct 201124 patients
Phase 1Completed
NCT04404296Alcon25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy

Pars Plana Vitrectomy With 25-gauge 20000 Cpm, Bevel-tip Cutter

Start: Apr 2021Est. completion: Jan 202250 patients
N/AUnknown
NCT04076072AlconUtravit High-Speed 10000 cpm Beveled Probe

Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe

Start: Sep 2019Est. completion: Jan 202240 patients
N/ACompleted
NCT01319318AbbViePars Plana Vitrectomy

Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy

Start: Mar 2011Est. completion: Jun 201225 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.